The Company notes overnight media reports in relation to multi-billion dollar transactions by global
pharmaceutical companies Gilead and Merck for companies active in the field of antibody drug
conjugates for the treatment of cancer. Patrys notes that whilst neither of these transactions directly
affects Patrys it reflects a strong international interest in assets and technologies like Patrys’
Deoxymab platform and PAT-DX1.
Ann: Response to ASX Price Query, page-2
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $9.338K | 1.167M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 103590 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 300000 | 1 |
View Market Depth
| Last trade - 15.05pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.8¢ | 266501 | ||
| Last updated 15.05pm 03/05/2024 ? | |||||
| PAB (ASX) Chart |